{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:31:29Z","timestamp":1767889889387,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whilst the issues around early termination of randomised controlled trials (RCTs) are well documented in the literature, trials can also be temporarily suspended with the real prospect that they may subsequently restart. There is little guidance in the literature as to how to manage such a temporary suspension. In this paper, we describe the temporary suspension of a trial within our clinical trials unit because of concerns over the safety of transvaginal synthetic mesh implants. We also describe the challenges, considerations, and lessons learnt during the suspension that we are now applying in the current COVID-19 pandemic which has led to activities in many RCTs across the world undergoing a temporary suspension.<\/jats:p><jats:p>There were three key phases within the temporary suspension: the decision to suspend, implementation of the suspension, and restarting. Each of these phases presented individual challenges which are discussed within this paper, along with the lessons learnt. There were obvious challenges around recruitment, delivery of the intervention, and follow-up. Additional challenges included communication between stakeholders, evolving risk assessment, updates to trial protocol and associated paperwork, maintaining site engagement, data-analysis, and workload within the trial team and Sponsor organisation.<\/jats:p><jats:p>Based on our experience of managing a temporary suspension, we developed an action plan and guidance (see Additional File 1) for managing a significant trial event, such as a temporary suspension. We have used this document to help us manage the suspension of activities within our portfolio of trials during the current COVID-19 pandemic.<\/jats:p>","DOI":"10.1186\/s13063-020-04705-4","type":"journal-article","created":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T06:02:53Z","timestamp":1599285773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["How to deal with a temporary suspension and restarting your trial: our experiences and lessons learnt"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9646-3904","authenticated-orcid":false,"given":"Lynda","family":"Constable","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Breeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonaidh","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Wileman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Norrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"key":"4705_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1745-6215-14-23","volume":"14","author":"B Choodari-Oskooei","year":"2013","unstructured":"Choodari-Oskooei B, Parmar MK, Royston P, Bowden J. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome. Trials. 2013;14:23\u20136215. https:\/\/doi.org\/10.1186\/1745-6215-14-23.","journal-title":"Trials"},{"key":"4705_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1745-6215-12-81","volume":"12","author":"P Royston","year":"2011","unstructured":"Royston P, Barthel FM, Parmar MK, Choodari-Oskooei B, Isham V. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials. 2011;12:81\u20136215. https:\/\/doi.org\/10.1186\/1745-6215-12-81.","journal-title":"Trials"},{"key":"4705_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","volume":"387","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387:1066\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(15)01167-8.","journal-title":"Lancet"},{"key":"4705_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jclinepi.2015.05.023","volume":"69","author":"M Stegert","year":"2016","unstructured":"Stegert M, Kasenda B, von Elm E, You JJ, Blumle A, Tomonaga Y, et al. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. J Clin Epidemiol. 2016;69:152\u201360. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.05.023.","journal-title":"J Clin Epidemiol"},{"key":"4705_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s43441-019-00050-0","volume":"54","author":"D Guinn","year":"2020","unstructured":"Guinn D, Wilhelm EE, Shoulson I. Reasons for premature conclusion of late phase clinical trials: an analysis of ClinicalTrials.gov registered phase III trials. Ther Innov Regul Sci. 2020;54:232\u20139. https:\/\/doi.org\/10.1007\/s43441-019-00050-0.","journal-title":"Ther Innov Regul Sci"},{"key":"4705_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0140-6736(16)00658-9","volume":"387","author":"J Norrie","year":"2016","unstructured":"Norrie J. ICON-6: the danger of changing study design midstream. Lancet. 2016;387:1031\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(16)00658-9.","journal-title":"Lancet"},{"key":"4705_CR7","doi-asserted-by":"crossref","unstructured":"Constable L, Davidson T, Wileman S, McCormack K, Thomas R, McDonald A, et al. Overcoming a trial \u2018adverse event\u2019: impact and experiences of a temporary suspension of randomisation in clinical trials. Trials. Vol 16, Supplement 2 (Abstract for Poster Presentation at 3rd International Clinical Trials Methodology Conference, Edinburgh, UK). 2015.","DOI":"10.1186\/1745-6215-16-S2-P178"},{"key":"4705_CR8","volume-title":"Rolling Updates on coronavirus disease (COVID-19)","author":"World Health Organisation (WHO)","year":"2020","unstructured":"World Health Organisation (WHO). Rolling Updates on coronavirus disease (COVID-19). 2020. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen. Accessed 17 July 2020."},{"key":"4705_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s13063-016-1576-x","volume":"17","author":"C Glazener","year":"2016","unstructured":"Glazener C, Constable L, Hemming C, Breeman S, Elders A, Cooper K, et al. Two parallel, pragmatic, UK multicentre, randomised controlled trials comparing surgical options for upper compartment (vault or uterine) pelvic organ prolapse (the VUE Study): study protocol for a randomised controlled trial. Trials. 2016;17:441\u2013016. https:\/\/doi.org\/10.1186\/s13063-016-1576-x.","journal-title":"Trials"},{"key":"4705_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24130","volume":"24","author":"C Hemming","year":"2020","unstructured":"Hemming C, Constable L, Goulao B, Kilonzo M, Boyers D, Elders A, et al. Surgical interventions for uterine prolapse and for vault prolapse: the two VUE RCTs. Health Technol Assess. 2020;24:1\u2013220. https:\/\/doi.org\/10.3310\/hta24130.","journal-title":"Health Technol Assess"},{"key":"4705_CR11","first-page":"2361","volume-title":"Scottish Parliament Public Petitions Committee: Polypropylene Mesh Medical Devices (PE1517)","author":"Scottish Parliament Public Petitions Committee","year":"2014","unstructured":"Scottish Parliament Public Petitions Committee. Scottish Parliament Public Petitions Committee: Polypropylene Mesh Medical Devices (PE1517); 2014. p. 2361\u201378."},{"key":"4705_CR12","unstructured":"Marsden H. Vaginal mesh to treat organ prolapse should be suspended, says UK health watchdog. UK: Independent; 2014. https:\/\/www.independent.co.uk\/news\/uk\/home-news\/vaginal-transvaginal-tvt-sling-mesh-scandal-nice-guidelines-health-watchdog-nhs-sui-incontinence-prolapse-hernia-a8111721.html."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-020-04705-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T23:28:02Z","timestamp":1630798082000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04705-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,5]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4705"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04705-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,5]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"765"}}